1. Home
  2. AKRO vs ASO Comparison

AKRO vs ASO Comparison

Compare AKRO & ASO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ASO
  • Stock Information
  • Founded
  • AKRO 2017
  • ASO 1938
  • Country
  • AKRO United States
  • ASO United States
  • Employees
  • AKRO N/A
  • ASO N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ASO Recreational Games/Products/Toys
  • Sector
  • AKRO Health Care
  • ASO Consumer Discretionary
  • Exchange
  • AKRO Nasdaq
  • ASO Nasdaq
  • Market Cap
  • AKRO 3.7B
  • ASO 3.3B
  • IPO Year
  • AKRO 2019
  • ASO 2020
  • Fundamental
  • Price
  • AKRO $54.07
  • ASO $46.20
  • Analyst Decision
  • AKRO Buy
  • ASO Buy
  • Analyst Count
  • AKRO 10
  • ASO 17
  • Target Price
  • AKRO $73.56
  • ASO $57.65
  • AVG Volume (30 Days)
  • AKRO 4.1M
  • ASO 1.7M
  • Earning Date
  • AKRO 11-07-2025
  • ASO 12-09-2025
  • Dividend Yield
  • AKRO N/A
  • ASO 1.10%
  • EPS Growth
  • AKRO N/A
  • ASO N/A
  • EPS
  • AKRO N/A
  • ASO 5.32
  • Revenue
  • AKRO N/A
  • ASO $5,971,497,000.00
  • Revenue This Year
  • AKRO N/A
  • ASO $4.02
  • Revenue Next Year
  • AKRO N/A
  • ASO $6.32
  • P/E Ratio
  • AKRO N/A
  • ASO $8.86
  • Revenue Growth
  • AKRO N/A
  • ASO N/A
  • 52 Week Low
  • AKRO $21.34
  • ASO $33.34
  • 52 Week High
  • AKRO $58.40
  • ASO $61.25
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 68.64
  • ASO 38.04
  • Support Level
  • AKRO $53.40
  • ASO $46.18
  • Resistance Level
  • AKRO $54.31
  • ASO $51.55
  • Average True Range (ATR)
  • AKRO 0.24
  • ASO 1.89
  • MACD
  • AKRO -0.18
  • ASO -0.52
  • Stochastic Oscillator
  • AKRO 74.03
  • ASO 2.19

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About ASO Academy Sports and Outdoors Inc.

Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.

Share on Social Networks: